|Bid||22.35 x 200|
|Ask||24.00 x 100|
|Day's Range||20.66 - 22.64|
|52 Week Range||5.47 - 23.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Renowned stockpicker Primecap Management made some interesting trades at the end of January, days before the market went topsy-turvy like the carousel in Strangers on a Train after the brake was applied. The fund manager sold positions in Eli Lilly (LLY), Rambus (RMBS) and tronc (TRNC) while lifting stakes in Spectrum Pharmaceuticals (SPPI) and United Continental Holdings (UAL). Primecap trimmed its investment in pharmaceutical giant Lilly by 731,200 shares to 55 million shares at Jan. 31 from Sept. 30.
Spectrum Pharmaceuticals' (SPPI) Rolontis meets primary endpoint in a phase III study for management of neutropenia in early stage breast cancer.
Bristol-Myers Squibb Company (NYSE:BMY) and Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) are both moving in the biotechnology space this week on the back of a couple of fresh data releases. Here’s what happened. Bristol-Myers Squibb This first one is rooted in a phase III trial that was set up to investigate the impact of a combination therapy […] The post Bristol-Myers Squibb, Spectrum Just Reported Key Late Stage Data appeared first on Market Exclusive.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) stock ...
After looking at Spectrum Pharmaceuticals Inc’s (NASDAQ:SPPI) latest earnings announcement (30 September 2017), I found it useful to revisit the company’s performance in the past couple of years and assessRead More...
Spectrum Pharmaceuticals Inc’s (NASDAQ:SPPI) released its most recent earnings update in September 2017, which indicated that losses became smaller relative to the prrior year’s level – great news for investorsRead More...
In 3Q17, Spectrum Pharmaceuticals (SPPI) raised $114.0 million from the sale of 12.6 million shares through its security offering program.
Spectrum Pharmaceuticals (SPPI) obtained exclusive rights to commercialize Poziotinib from Hanmi Pharmaceutical (HANPF) under an in-license agreement in 2015.
In 2012, Spectrum Pharmaceuticals (SPPI) acquired the rights to market Zevalin outside the US from Bayer for 19 million euros.
Spectrum Pharmaceuticals (SPPI) acquired Talon Therapeutics in July 2013 for $11.3 million in cash and an issuance of 3.0 million shares.
Biotech firm Spectrum Pharmaceuticals (SPPI) develops oncology and hematology drug products. SPPI generates ~90% of its revenues from the US market, and ~10% of its revenues come from Europe.
Spectrum (SPPI) focuses on developing pipeline candidates. The stock doubled in the last three months mainly on encouraging data from poziotinib study.
If you notice a relative who can't stop grinning at the Thanksgiving dinner table, they're probably holding shares of these biotech stocks.
Ligand's (LGND) earnings and revenues beat estimates. Total revenues also rise year over year on the back of higher royalty benefits. The company ups its guidance for 2017.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Spectrum Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to SPPI-US. Comparing the performance and risk of Spectrum Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)